Paratek Pharmaceuticals, Inc.
PRTK•NASDAQ
Paratek Pharmaceuticals, Inc.
PRTK•NASDAQ
Sentiment
Phase 1 · Company Overview
Step 1: Overview
What the company does, where it operates, and who runs it.
Overview for Paratek Pharmaceuticals, Inc.
Industry:Biotechnology
Sector:Healthcare
CEO:Evan Loh FACC, FAHA,
Description:Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Address:N/A
Step 2: Infographics
Visual summary of the business at a glance.
Phase 2 · FRC Research
Step 3: Media
Videos and interviews covering the company.
Phase 3 · Financial Data
Step 4: Stock Data
Price chart, volume, and trading data.
PRTK Stock Price
Step 5: Fair Value
What FRC thinks the stock is worth vs. the current price.
Step 6: Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Step 7: Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Step 8: Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Step 9: Financial Statements
Income statement, balance sheet, and cash flow statements.
Phase 4 · Peer Comparison
Step 10: Comparables
List of peer companies in the same industry.
Phase 5 · Ownership & News
Step 12: Institutional Ownership
Which funds and firms own the stock.
Step 13: Insider Trading
Recent buying and selling by company executives.
Step 14: Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
Step 15: News
Latest headlines and market coverage.
News
Latest Market News